These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8648400)

  • 1. Paclitaxel and doxorubicin in metastatic breast cancer.
    Sharma S
    J Clin Oncol; 1996 Apr; 14(4):1403. PubMed ID: 8648400
    [No Abstract]   [Full Text] [Related]  

  • 2. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.
    Hortobagyi GN; Holmes FA; Theriault RL; Rahman Z; Buzdar AU
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-13-S11-19. PubMed ID: 9314293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac dysfunction in cancer patients receiving paclitaxel.
    Valdés Olmos RA; ten Bokkel Huinink WW; Hoefnagel CA
    Eur J Nucl Med; 1998 Apr; 25(4):446-7. PubMed ID: 9643974
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
    Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin/paclitaxel combination does not expose breast cancer patients to excessive cardiac risk.
    Oncology (Williston Park); 2001 Jul; 15(7):830. PubMed ID: 11499684
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
    Paridaens R
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience.
    Gianni L
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):13-5. PubMed ID: 9516596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
    Piccart-Gebhart MJ; Bruning P; Gamucci T; Klijn J; Roy JA; Awada A; Kusenda Z; Van Vreckem A; Paridaens R
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):11-5. PubMed ID: 8893893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Paclitaxel in therapy of breast carcinoma. Value and perspectives].
    Klaassen U; Seeber S
    Med Klin (Munich); 1996 Dec; 91 Suppl 2():7-10. PubMed ID: 9082172
    [No Abstract]   [Full Text] [Related]  

  • 15. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
    Gennari A; Amadori D; De Lena M; Nanni O; Bruzzi P; Lorusso V; Manzione L; Conte PF
    J Clin Oncol; 2006 Aug; 24(24):3912-8. PubMed ID: 16921042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
    Buzdar AU; Singletary SE; Valero V; Booser DJ; Ibrahim NK; Rahman Z; Theriault RL; Walters R; Rivera E; Smith TL; Holmes FA; Hoy E; Frye DK; Manuel N; Kau SW; McNeese MD; Strom E; Thomas E; Hunt K; Ames F; Berry D; Hortobagyi GN
    Clin Cancer Res; 2002 May; 8(5):1073-9. PubMed ID: 12006521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin plus paclitaxel in advanced breast cancer.
    Dombernowsky P; Boesgaard M; Andersen E; Jensen BV
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-15-S17-8. PubMed ID: 9374086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
    Hortobagyi GN; Willey J; Rahman Z; Holmes FA; Theriault RL; Buzdar AU
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-65-S17-68. PubMed ID: 9374097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.